Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: A randomized trial

Annals of Internal Medicine

Volumn 155, Issue 4, 2011, Pages 217-226

  Wang, Chen ^a   Cao, Bin ^b   Liu, Qing Quan ^c   Zou, Zhi Qiang ^d   Liang, Zong An ^e   Gu, Li ^b   Dong, Jian Ping ^f   Liang, Li Rong ^b   Li, Xing Wang ^g   Hu, Ke ^h   He, Xue Song ⁱ   Sun, Yan Hua ^j   An, Yu ^k   Yang, Ting ^b   Cao, Zhi Xin ^b   Guo, Yan Mei ^d   Wen, Xian Min ^l   Wang, Yu Guang ^g   Liu, Ya Ling ^l   Jiang, Liang Duo ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^d Yantai Infectious Disease Hospital   (China)

^e SICHUAN UNIVERSITY   (China)

^f Beijing Haidian Hospital   (China)

^g CAPITAL MEDICAL UNIVERSITY   (China)

^h RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

ⁱ Changxindian Hospital of Fengtai District of Beijing   (China)

^j Department of Ultrasound   (China)

^k The Second Hospital of Beijing   (China)

^l Chengdu Infectious Disease Hospital   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CHINESE DRUG; MAXINGSHIGAN YINQIAOSAN; OSELTAMIVIR; PARACETAMOL; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AGED; ARTICLE; CHINA; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HUMAN; INFLUENZA A (H1N1); MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS SHEDDING; VIRUS TITRATION; VOMITING;

EID: 80051654005     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-155-4-201108160-00005     Document Type: Article

References (35)

1. Centers for Disease Control and Prevention (CDC). Swine influenza A (H1N1) infection in two children-Southern California, March-April 2009. MMWR Morb Mortal Wkly Rep. 2009;58:400-2. [PMID: 19390508]
2. Centers for Disease Control and Prevention (CDC). Outbreak of swineorigin influenza A (H1N1) virus infection-Mexico, March-April 2009. MMWR Morb Mortal Wkly Rep. 2009;58:467-70. [PMID: 19444150]
3. Centers for Disease Control and Prevention (CDC). Update: infections with a swine-origin influenza A (H1N1) virus-United States and other countries, April 28, 2009. MMWR Morb Mortal Wkly Rep. 2009;58:431-3. [PMID: 19407737]
4. Pandemic (H1N1) 2009-update 94. Geneva: World Health Organization; 1 April 2010. Accessed at www.who.int/csr/don/2010_04_01/en/index.html on 9 April 2010
5. Cao B, Li XW, Mao Y, Wang J, Lu HZ, Chen YS, et al; National Influenza A Pandemic (H1N1) 2009 Clinical Investigation Group of China. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med. 2009;361:2507-17. [PMID: 20007555]
6. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, et al; 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009;361:1935-44. [PMID: 19815859]
7. Domínguez-Cherit G, Lapinsky SE, Macias AE, Pinto R, Espinosa-Perez L, de la Torre A, et al. Critically Ill patients with 2009 influenza A(H1N1) in Mexico. JAMA. 2009;302:1880-7. [PMID: 19822626]
8. WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 Influenza and Other Influenza Viruses. Geneva: World Health Organization; 20 August 2009. Accessed at www.who.int/csr/resources/publications/swineflu/h1n1_guidelines_pharmaceutical_mngt.pdf on 10 June 2011
9. Uyeki T. Antiviral treatment for patients hospitalized with 2009 pandemic influenza A (H1N1). N Engl J Med. 2009;361:e110. [PMID: 19923564]
10. Baz M, Abed Y, Papenburg J, Bouhy X, Hamelin ME, Boivin G. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis [Letter]. N Engl J Med. 2009;361:2296-7. [PMID: 19907034]
11. Chan K. Chinese medicinal materials and their interface with Western medical concepts. J Ethnopharmacol. 2005;96:1-18. [PMID: 15588645]
12. Wang J, Cheng SH, Zhang JY. A systematic review of chuanhuning for acute respiratory tract infections. Chinese Archives of Traditional Chinese Medicine. 2007;25:2200-3.
13. Chen N, Ren L. [Modern pharmacology research and clinical use of maxingshigan]. Academic Journal of Guang Dong College of Pharmacy. 2004;545-6.
14. Huang JM, Chen DP, Yang LP. [The immunomodulating effects of maxingshigan on asthma mice models]. Journal of Fujian Traditional Chinese Medicine. 2003;34:38-9.
15. Chinese Pharmacopoeia Commission. [Pharmacopoeia of the People's Republic of China]. Beijing: People's Medical Publishing House; 2005.
16. World Health Organization. CDC Protocol of Realtime RTPCR for Influenza A (H1N1). Geneva: World Health Organization; 28 April 2009. Accessed at www.who.int/csr/resources/publications/swineflu/CDCRealtimeRTPCR_SwineH1Assay-2009_20090430.pdf on 10 June 2011.
17. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet. 2000;355:1845-50. [PMID: 10866439]
18. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000;283:1016-24. [PMID: 10697061]
19. Patel K, Kay R, Rowell L. Comparing proportional hazards and accelerated failure time models: an application in influenza. Pharm Stat. 2006;5:213-24. [PMID: 17080754]
20. Cheng JT. Review: drug therapy in Chinese traditional medicine. J Clin Pharmacol. 2000;40:445-50. [PMID: 10806595]
21. Zhao WN, Lu FG, Zhang W, Zhu YW, He YC. Effect of maxing shigan decoction and its alteration on mice T-cell subpopulation exposed to influenza virus A. Practical Preventive Medicine. 2007;14:178-280.
22. Guo F, He YC, Xiao ZZ, Wu CR, Zhang W, Li S, et al. Study on effect target of maxing shigan decoction on anti-influenza virus A in vitro. Journal of Traditional Chinese Medicine University of Hunan. 2008;28:5-9.
23. Zhang W, Lu FG, He YC, Xiao ZZ, Lu XH, Zhu YW, et al. Experimental study on effect of maxing shigan decoction on anti-influenza virus A in vitro. Practical Preventive Medicine. 2007;14:1351-3.
24. Poon PM, Wong CK, Fung KP, Fong CY, Wong EL, Lau JT, et al. Immunomodulatory effects of a traditional Chinese medicine with potential antiviral activity: a self-control study. Am J Chin Med. 2006;34:13-21. [PMID: 16437735]
25. Chow MS, Chang Q, Zuo J. Herb-drug interaction involving oseltamivir and Chinese medicine formula [Abstract]. FASEB J. 2008;22(Suppl):1136-24.
26. U.S. Food and Drug Administration. Dietary supplements containing ephedrine alkaloids. 22 August 2006. Accessed at www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm152388.htm on 10 June 2011
27. Health Canada requests recall of certain products containing ephedra/ephedrine. 6 February 2007. Accessed at www.preventivehealthtoday.com/alerts/hc _ephedra_020109.html on 10 June 2011
28. Hallas J, Bjerrum L, Støvring H, Andersen M. Use of a prescribed ephedrine/ caffeine combination and the risk of serious cardiovascular events: a registrybased case-crossover study. Am J Epidemiol. 2008;168:966-73. [PMID: 18756018]
29. Andraws R, Chawla P, Brown DL. Cardiovascular effects of ephedra alkaloids: a comprehensive review. Prog Cardiovasc Dis. 2005;47:217-25. [PMID: 15991150]
30. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med. 2000;343:1833-8. [PMID: 11117974]
31. Soni MG, Carabin IG, Griffiths JC, Burdock GA. Safety of ephedra: lessons learned. Toxicol Lett. 2004;150:97-110. [PMID: 15068827]
32. Yan Y, Zhan L, Chen Z, Kang C. [Changes of ephedrine and pseudoephedrine content in Herba Ephedrae before and after honeybaking]. West China Journal of Pharmaceutical Sciences. 2007;22:559-61.
33. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005; 353:1363-73. [PMID: 16192481]
34. Jefferson T, Jones M, Doshi P, Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and metaanalysis. BMJ. 2009;339:b5106. [PMID: 19995812]
35. Dharan NJ, Gubareva LV, Meyer JJ, Okomo-Adhiambo M, McClinton RC, Marshall SA, et al; Oseltamivir-Resistance Working Group. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA. 2009; 301:1034-41. [PMID: 19255110]